Overview
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-07-01
2025-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumorPhase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical CenterCollaborator:
Ministry of Health, Republic of KoreaTreatments:
Carboplatin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Criteria
Inclusion Criteria:- Patients with refractory/relapsed solid tumor (Stable or progressive disease after
1st-line treatment or relapse)
- Patients previously enrolled to "Genomic diagnosis of pediatric tumors by NGS (IRB No.
SMC 2015-11-053)"
Exclusion Criteria:
- Patients who had high-dose chemotherapy and autologous stem cell transplantation
previously
- Patients with organ dysfunction as follows (creatinine elevation ≥ 1.5 x upper limit
of normal (ULN), ejection fraction <40%, significant arrhythmia or conduction
disturbance)
- Patients who are not eligible to have scheduled treatment due to the other significant
impaired organ function
- Patients with active bleeding
- Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic
agents, or anti-platelet agents
- Pregnant or nursing women
- Patients who can not swallow the pill